July 31 (Reuters) - Biogen raised its annual
profit forecast on Thursday, betting on strong demand for its
rare disease drugs such as Skyclarys to offset declining sales
of its older multiple sclerosis drugs.
On an adjusted basis, Biogen expects 2025 adjusted per-share
profit between $15.50 and $16.00, compared with its previous
forecast of between $14.50 and $15.50.